Denosumab biosimilar - Samsung Bioepis
Alternative Names: OBODENCE; SB-16; XBRYKLatest Information Update: 28 Dec 2024
Price :
$50 *
At a glance
- Originator Samsung Bioepis
- Class Antihypercalcaemics; Antineoplastics; Antirheumatics; Calcium regulators; Immunotherapies; Monoclonal antibodies; Osteoporosis therapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; RANK ligand inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preregistration Bone disorders; Bone metastases; Corticosteroid-induced osteoporosis; Giant cell tumour of bone; Male osteoporosis; Malignant hypercalcaemia; Postmenopausal osteoporosis
- No development reported Osteoporosis